The medical imaging firm said it believed the StoneChecker software, now approved for sale in the US market, was using its TexRAD software
() shares surged on Friday after StoneChecker Software, a product of () subsidiary Imaging Biometrics, received regulatory clearance by the US Food and Drug Administration (FDA).
StoneChecker, which is used to assess kidney stones, is a licensee of Feedback’s TexRAD software, however, the medical imaging firm it was currently not able to evaluate the level of income it would accrue as a result of the FDA clearance.
That didn’t stop the excitement from investors, as the shares jumped 16.3% to 1.3p in late-afternoon trading.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Feedback PLC named herein, including the promotion by the Company of Feedback PLC in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE